These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7130327)

  • 1. Rapid and simple method for determination of lorcainide, a new antiarrhythmic drug, and its major metabolite, norlorcainide, by high-performance liquid chromatography.
    Simon V; Somani P
    J Chromatogr; 1982 Sep; 231(2):478-84. PubMed ID: 7130327
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.
    Mead RH; Keefe DL; Kates RE; Winkle RA
    Am J Cardiol; 1985 Jan; 55(1):72-8. PubMed ID: 2578245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [HPLC method for determination of lorcainide hydrochloride in human serum].
    Luo X; Zeng FD
    Yao Xue Xue Bao; 1995; 30(8):605-9. PubMed ID: 8571780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative electrophysiology of lorcainide and norlorcainide in the dog.
    Keefe DL; Kates RE; Winkle RA
    J Cardiovasc Pharmacol; 1984; 6(5):808-15. PubMed ID: 6209484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic analysis of lorcainide and its active metabolite, norlorcainide, in human plasma.
    Yee YG; Kates RE
    J Chromatogr; 1981 May; 223(2):454-9. PubMed ID: 7251802
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    Echt DS; Mitchell LB; Kates RE; Winkle RA
    Circulation; 1983 Aug; 68(2):392-9. PubMed ID: 6861314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
    Winkle RA; Keefe DL; Rodriguez I; Kates RE
    Am J Cardiol; 1984 Feb; 53(4):544-51. PubMed ID: 6198895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lorcainide disposition kinetics in arrhythmia patients.
    Kates RE; Keefe DL; Winkle RA
    Clin Pharmacol Ther; 1983 Jan; 33(1):28-34. PubMed ID: 6848296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal lorcainide poisoning.
    Evers J; Büttner-Belz U
    J Toxicol Clin Toxicol; 1995; 33(2):157-9. PubMed ID: 7897755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison in vitro of the electrophysiological effects of lorcainide and its metabolite norlorcainide.
    Carmeliet E
    Eur J Pharmacol; 1987 Jan; 133(1):29-36. PubMed ID: 3556390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of lorcainide.
    Keefe DL
    Am J Cardiol; 1984 Aug; 54(4):18B-21B. PubMed ID: 6465043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
    Vlay SC; Mallis GI
    Am Heart J; 1986 Mar; 111(3):452-5. PubMed ID: 3953352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic effect of lorcainide in patients taking digoxin.
    Giardina EG; Raby K; Saroff AL; Louie-Chu M
    J Clin Pharmacol; 1987; 27(5):378-83. PubMed ID: 3693581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term lorcainide therapy guided by electrophysiology studies.
    Somberg J; Butler B; Flowers D; Tepper D; Torres V
    Acta Cardiol; 1985; 40(6):621-36. PubMed ID: 3879419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of enzyme induction on the disposition of lorcainide in rats following intravenous and oral administration.
    Plänitz V; Jähnchen E
    Arzneimittelforschung; 1984; 34(6):669-71. PubMed ID: 6541487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorcainide in patients with refractory ventricular tachyarrhythmia.
    Chesnie B; Lampert S; Podrid P; Lown B
    J Am Coll Cardiol; 1984 Jun; 3(6):1531-9. PubMed ID: 6715710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of flecainide and lorcainide in blood by means of TLC.
    Paw B; Przyborowski L
    Acta Pol Pharm; 1995; 52(1):5-7. PubMed ID: 8960234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use and limitations of deuterated lorcainide in metabolism and pharmacokinetic studies.
    Gelijkens CF; Van Peer A; Lenoir H; Knaeps A; Woestenborghs R; Heykants J
    Biomed Mass Spectrom; 1985 Jan; 12(1):38-42. PubMed ID: 3157409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of the newer antiarrhythmic agents.
    Gillis AM; Kates RE
    Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce; Brogden RN
    Drugs; 1984 Apr; 27(4):279-300. PubMed ID: 6373222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.